Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS

Neurology. 2006 Nov 14;67(9):1681-3. doi: 10.1212/01.wnl.0000242884.76598.bb.

Abstract

We measured neutralizing antibodies (NABs) and the in vivo biologic response to interferon-beta on neopterin and beta(2)-microglobulin blood levels. All NAB-negative patients had an in vivo biologic response (full or partial), whereas all high-level positive patients had no response. High-level NAB patients had more MRI activity than NAB-negative patients (p = 0.031). Patients with a full response had less MRI activity than patients without biologic response (p = 0.032).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies / blood*
  • Brain / drug effects
  • Brain / immunology
  • Brain / pathology
  • Disease Progression
  • Drug Resistance / immunology*
  • Female
  • Humans
  • Interferon-beta / antagonists & inhibitors*
  • Interferon-beta / immunology*
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Multiple Sclerosis / blood
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / immunology*
  • Neopterin / blood
  • Neopterin / immunology
  • Treatment Outcome

Substances

  • Antibodies
  • Neopterin
  • Interferon-beta